耐药结核接触者综合预防性治疗方案:莫西沙星或贝达喹啉的安全性、有效性与可接受性
该回顾性队列研究在俄罗斯弗拉基米尔市2019–2020年开展,403名耐药结核接触者接受6种预防性治疗方案之一。结果显示无危及生命的不良反应或死亡,3Bdq方案不良反应率最低、完成率最高(95.2%),拒绝预防性治疗者结核发病率是启动者的4倍。
要点
- 未发生危及生命的不良反应或死亡。
- 拒绝预防性治疗的合格个体结核发病率是启动者的4倍。
核心结论
- 针对耐药结核(包括氟喹诺酮耐药株)的预防性治疗可接受、安全且有效。
研究设计与样本
- 2019–2020年俄罗斯弗拉基米尔市回顾性队列研究,纳入接受预防性治疗的成人结核接触者、无家可归者和HIV感染者共403人。
主要发现
- 24个月内403人启动预防性治疗,未发生危及生命的不良反应或死亡。
- 拒绝预防性治疗的合格个体结核发病率是启动者的4倍(每1000人年)。
关键数值与推荐
- 根据指示病例的药敏试验结果提供6种方案之一:3HP、6H、3HRb、4R、4Mfx或3Bdq。
临床怎么用
- 在高耐药结核负担地区实施综合预防性治疗项目可保护接触者并减少传播。
- 贝达喹啉方案(3Bdq)表现出最低不良反应率和最高完成率,可作为优先选择之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rates of drug-resistant tuberculosis (DR-TB) are increasing worldwide. Tuberculosis preventive treatment (TPT) for contacts of people with active TB is essential to halt infection progression and transmission. While newer TPT regimens for exposure to drug-susceptible and rifampin (R)-resistant strains (MDR-TB/RR-TB) are expanding, optimal treatment for contacts exposed to fluoroquinolone-resistant strains of TB (pre-XDR- or XDR-TB) remains unclear. In 2019-2020, Vladimir City, Russia, introduced moxifloxacin (Mfx)- and bedaquiline (Bdq)-based TPT regimens to prevent disease development in contacts exposed to MDR/RR-TB and pre-XDR-TB. METHODS: We conducted a retrospective cohort study of adult TB contacts, people experiencing homelessness, and people with HIV who received TPT in Vladimir between 2019 and 2020. Those without TB disease but with indications for TPT were offered 1 of 6 regimens, based on drug-susceptibility testing results of the index patient: rifapentine/isoniazid (3HP), isoniazid (6H), rifabutin/isoniazid (3HRb), 4R, 4Mfx, or 3Bdq. Adverse drug reactions (ADRs) were monitored with monthly lab tests and electrocardiogram (ECGs). Outcome measures included ADRs, TPT completion, and TB disease incidence during the 12-month follow-up period. RESULTS: Over 24 months, 403 people started TPT. No life-threatening ADRs or deaths occurred. The lowest ADR rate and highest completion were seen with 3Bdq (95.2%) compared to 3HP (75.9%, Mid-P exact = .03). Tuberculosis incidence per 1000 person-years was 4 times higher among eligible individuals who declined TPT versus those initiating it. CONCLUSIONS: Preventive therapy for drug-resistant TB, including fluoroquinolone-resistant strains, is acceptable, safe, and effective. Implementation of comprehensive TPT programs in high-burden DR-TB settings can protect contacts and reduce transmission.
引用
- Solovyeva AV, Volchenkov GV, Ponomarenko OI, et al. Implementing a Program of Comprehensive Tuberculosis Preventive Treatment: Safety, Effectiveness, and Acceptability of Moxifloxacin or Bedaquiline Use for Contacts Exposed to Drug-Resistant Strains. Clin Infect Dis. 2026. PMID: 41631511. doi:10.1093/cid/ciaf701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。